Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics.

被引：6

作者：

Daniel Aletaha

Josef S. Smolen

机构：

[1] Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18-20, Vienna

来源：

关键词：

Rheumatoid Arthritis; Leflunomide; Anakinra; Drug Survival; High Disease Activity;

D O I：

10.1007/s11926-003-0048-y

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

页码：409 / 412

页数：3

共 9 条

[1]

Wolfe F(1999)Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology J Rheumatol 26 484-489

[2]

Lassere M(1999)Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies Ann Rheum Dis 58 I82-I85

[3]

van der HD G(1990)Reevaluating the therapeutic approach to rheumatoid arthritis: the “sawtooth” strategy J Rheumatol 22 12-15

[4]

Stucki C(2002)The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses Rheumatology (Oxford) 41 1367-1374

[5]

Bombardier A(undefined)undefined undefined undefined undefined-undefined

[6]

Maetzel JF(undefined)undefined undefined undefined undefined-undefined

[7]

Fries D(undefined)undefined undefined undefined undefined-undefined

[8]

Aletaha JS(undefined)undefined undefined undefined undefined-undefined

[9]

Smolen undefined(undefined)undefined undefined undefined undefined-undefined